Skye Bioscience Inc (SKYE)

[Vinpat]

That's solid analysis. I think InMed has potential but I can't justify a $60 million valuation with 100m outstanding shares while Nemus has a $7 million valuation with 25m outstanding shares. Nemus has numerous patents and is 2-3 years ahead of InMed with their drug candidates. InMed has one pending patent and theire's silence on their alleged pending patent for glaucoma announced 2 years ago. Could it be Nemus beat them to it and they can't get it?

But InMed has something as there are good people involved now and they have been able to raise money.